NLS Pharmaceuticals to Reschedule Company Update on Strategic Discussions

ACCESSWIRE2023-10-19

ZURICH, SWITZERLAND / ACCESSWIRE / October 19, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that it will postpone the company update previously scheduled for Friday, October 20, 2023, due to important developments impacting the timing of the event.

About NLS Pharmaceutics Ltd.

NLS Pharmaceutics Ltd. (Nasdaq:NLSP) is a global development-stage biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders who have unmet medical needs. Headquartered in Switzerland and founded in 2015, NLS is led by an experienced management team with a track record of developing and commercializing product candidates. For more information, please visit www.nlspharma.com.

For additional information:

Marianne Lambertson (investors & media)
NLS Pharmaceutics Ltd.
ml@nls-pharma.com
www.nlspharmaceutics.com

SOURCE: NLS Pharmaceutics AG

View source version on accesswire.com:
https://www.accesswire.com/794639/nls-pharmaceuticals-to-reschedule-company-update-on-strategic-discussions

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2376254954?lang=en_US&edition=full_marsco","thumbnail":"https://s.yimg.com/uu/api/res/1.2/OhxsYLQy5hhKTa5XXhiESQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/0f69861f36fd4cda31b6044a0d86ae26","is_english":true,"pubTime":"2023-10-20 05:00","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2376254954","market":"us","top_or_hot":-1,"title":"NLS Pharmaceuticals to Reschedule Company Update on Strategic Discussions","media":"ACCESSWIRE","content":"<html><body><p><strong>ZURICH, SWITZERLAND / ACCESSWIRE / October 19, 2023 / </strong><a href=\"https://laohu8.com/S/NLSP\">NLS Pharmaceutics Ltd.</a> (Nasdaq:NLSP, NLSPW) (\"NLS\" or the \"Company\"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that it will postpone the company update previously scheduled for Friday, October 20, 2023, due to important developments impacting the timing of the event.</p>\n<p><strong>About NLS Pharmaceutics Ltd.</strong></p>\n<p>NLS Pharmaceutics Ltd. (Nasdaq:NLSP) is a global development-stage biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders who have unmet medical needs. Headquartered in Switzerland and founded in 2015, NLS is led by an experienced management team with a track record of developing and commercializing product candidates. For more information, please visit www.nlspharma.com.</p>\n<p><strong>For additional information:</strong></p>\n<p>Marianne Lambertson (investors &amp; media) <br/>NLS Pharmaceutics Ltd.<br/>ml@nls-pharma.com<br/>www.nlspharmaceutics.com</p>\n<p><strong>SOURCE: </strong>NLS Pharmaceutics AG</p>\n<br/>\n<br/>View source version on accesswire.com: \n<br/>\nhttps://www.accesswire.com/794639/nls-pharmaceuticals-to-reschedule-company-update-on-strategic-discussions\n<br/>\n<br/>\n<br/>\n<br/>\n<br/>\n<br/></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NLS Pharmaceuticals to Reschedule Company Update on Strategic Discussions</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNLS Pharmaceuticals to Reschedule Company Update on Strategic Discussions\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-10-20 05:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/nls-pharmaceuticals-reschedule-company-strategic-210000509.html><strong>ACCESSWIRE</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ZURICH, SWITZERLAND / ACCESSWIRE / October 19, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) (\"NLS\" or the \"Company\"), a Swiss clinical-stage biopharmaceutical company focused on the discovery ...</p>\n\n<a href=\"https://finance.yahoo.com/news/nls-pharmaceuticals-reschedule-company-strategic-210000509.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://finance.yahoo.com/news/nls-pharmaceuticals-reschedule-company-strategic-210000509.html","article_id":"2376254954","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/OhxsYLQy5hhKTa5XXhiESQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/0f69861f36fd4cda31b6044a0d86ae26"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2376254954","pubTimestamp":1697749200,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"ZURICH, SWITZERLAND / ACCESSWIRE / October 19, 2023 / NLS Pharmaceutics Ltd.  , a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that it will postpone the company update previously scheduled for Friday, October 20, 2023, due to important developments impacting the timing of the event.NLS Pharmaceutics Ltd.  is a global development-stage biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders who have unmet medical needs. Headquartered in Switzerland and founded in 2015, NLS is led by an experienced management team with a track record of developing and commercializing product candidates. For more information, please visit www.nlspharma.com.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"NLS制药将重新安排公司战略讨论的最新进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BFX":1,"NLS":1,"NLSP":0.9,"NLSPW":0.9},"content_text":"ZURICH, SWITZERLAND / ACCESSWIRE / October 19, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) (\"NLS\" or the \"Company\"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that it will postpone the company update previously scheduled for Friday, October 20, 2023, due to important developments impacting the timing of the event.\nAbout NLS Pharmaceutics Ltd.\nNLS Pharmaceutics Ltd. (Nasdaq:NLSP) is a global development-stage biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders who have unmet medical needs. Headquartered in Switzerland and founded in 2015, NLS is led by an experienced management team with a track record of developing and commercializing product candidates. For more information, please visit www.nlspharma.com.\nFor additional information:\nMarianne Lambertson (investors & media) NLS Pharmaceutics Ltd.ml@nls-pharma.comwww.nlspharmaceutics.com\nSOURCE: NLS Pharmaceutics AG\n\nView source version on accesswire.com: \n\nhttps://www.accesswire.com/794639/nls-pharmaceuticals-to-reschedule-company-update-on-strategic-discussions","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2376254954"}